Evaluating p53 Polymorphisms in Breast Cancer Risk for BRCA1 and BRCA2 Carriers
Author Information
Author(s): Osorio A, Pollán M, Pita G, Schmutzler R K, Versmold B, Engel C, Meindl A, Arnold N, Preisler-Adams S, Niederacher D, Hofmann W, Gadzicki D, Jakubowska A, Hamann U, Lubinski J, Toloczko-Grabarek A, Cybulski C, Debniak T, Llort G, Yannoukakos D, Díez O, Peissel B, Peterlongo P, Radice P, Heikkinen T, Nevanlinna H, Mai P L, Loud J T, McGuffog L, Antoniou A C, Benitez J
Primary Institution: Spanish National Cancer Centre (CNIO)
Hypothesis
Do p53 polymorphisms Ins16bp and Arg72Pro modify breast cancer risk in BRCA1 and BRCA2 mutation carriers?
Conclusion
The study found no evidence that the p53 polymorphisms Ins16bp and Arg72Pro modify breast or ovarian cancer risk in BRCA1/2 mutation carriers.
Supporting Evidence
- The study included a large sample size of 2932 BRCA1/2 mutation carriers.
- Previous studies suggested a link between p53 polymorphisms and breast cancer risk, but this study found no such association.
- The research highlights the importance of larger studies to confirm genetic associations.
Takeaway
Scientists looked at two gene changes to see if they affect breast cancer risk in people with certain genetic mutations, but they found no link.
Methodology
The study evaluated the association of p53 polymorphisms in a large series of BRCA1/2 mutation carriers using genotyping and statistical analysis.
Limitations
The study did not find confirmation of previously reported associations, highlighting the need for larger collaborative studies.
Participant Demographics
The study included 2088 BRCA1 mutation carriers, 841 BRCA2 mutation carriers, and 3 carriers of mutations in both genes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website